Mangoceuticals, Inc. (MGRX) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Mangoceuticals, Inc. (MGRX) stock forecast summary
On Oct. 13, 2026, MGRX is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
Mangoceuticals, Inc. is a small-cap company with a market capitalization of $8M. It ranks number 11 by market capitalization among the 11 Services-Misc Health & Allied Services, NEC issuers in our coverage with a current forecast. Its Net Margin of -6539.3% is the lowest of the 10 peers that report one. Its Current Ratio of 0.18x is the lowest of the 11 peers that report one.
A per-ticker accuracy statistic for MGRX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, MGRX included.
Follow MGRX freeMGRX price chart and AI forecast
How MGRX ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Mangoceuticals, Inc. (MGRX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Misc Health & Allied Services, NEC peers listed below that report each metric.
Valuation & Market
| Metric | MGRX | Rank |
|---|---|---|
| Market Cap | $8M | 11/11 |
| P/B Ratio | 0.66x | 7/7 |
| EPS | $-1.35 | – |
| Book Value/Share | $0.58 | – |
Profitability & Margins
| Metric | MGRX | Rank |
|---|---|---|
| ROE | -159.3% | 6/7 |
| ROA | -140.8% | 8/10 |
| ROIC | -132.8% | 8/8 |
| Gross Margin | 70.2% | 2/6 |
| Operating Margin | -5562.1% | 8/9 |
| Net Margin | -6539.3% | 10/10 |
| EBT Margin | -5817.7% | 9/10 |
Financial Health
| Metric | MGRX | Rank |
|---|---|---|
| Current Ratio | 0.18x | 11/11 |
| D/E Ratio | 0.13x | 8/9 |
| Financial Leverage | 1.13x | 8/9 |
| Working Capital | -$1M | 9/11 |
Cash Flow
| Metric | MGRX | Rank |
|---|---|---|
| Operating Cash Flow | -$4M | 8/11 |
Income Statement
| Metric | MGRX | Rank |
|---|---|---|
| Operating Income | -$16M | 9/10 |
| Net Income | -$19M | 9/10 |
| Cost of Goods Sold | $40K | 7/8 |
Dividend & Shareholder Information
| Metric | MGRX | Rank |
|---|---|---|
| Shares Outstanding | 22M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $250K | 1.8% of assets |
| Cash & Short-term Investments | $230K | 1.6% of assets |
| Total Liabilities | $2M | 11.6% of assets |
MGRX quarterly financials and insider trading
Mangoceuticals, Inc. (MGRX) industry peers
Companies classified under the same SEC industry code as Mangoceuticals, Inc. (Services-Misc Health & Allied Services, NEC): 13 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| MGRX Mangoceuticals, Inc. | ▶ | $8M |
| DVA Davita Inc. | ▶ | $11.62B |
| FMS Fresenius Medical Care Ag | ▼ | $5.89B |
| SHC Sotera Health Co | ▼ | $5.20B |
| PGNY Progyny, Inc. | ▶ | $2.10B |
| AGL Agilon Health, Inc. | ▶ | $1.44B |
| VMD Viemed Healthcare, Inc. | ▲ | $366M |
| PARK Park Dental Partners, Inc. | ▲ | $96M |
| MRAI Marpai, Inc. | ▲ | $87M |
| CCEL Cryo Cell International Inc | ▲ | $36M |
| PFHO Pacific Health Care Organization Inc | ▲ | $12M |
| BRTX Biorestorative Therapies, Inc. | ▶ | N/A |
| NIVF Newgenivf Group Ltd | ▼ | N/A |
Where MGRX sits on the market map
Mangoceuticals, Inc. (MGRX) stock news
Loading...
Mangoceuticals, Inc. (MGRX) stock forecast FAQ
What is the Mangoceuticals, Inc. (MGRX) stock forecast?
On Oct. 13, 2026, MGRX is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
How accurate are Mangoceuticals, Inc. stock predictions?
A per-ticker accuracy statistic for MGRX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Mangoceuticals, Inc. forecasts updated?
Mangoceuticals, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Mangoceuticals, Inc.'s industry peers?
13 issuers in our coverage, MGRX included, share the SEC industry code Services-Misc Health & Allied Services, NEC. The largest are: Davita Inc. (DVA), Fresenius Medical Care Ag (FMS), Sotera Health Co (SHC), Progyny, Inc. (PGNY), Agilon Health, Inc. (AGL), Viemed Healthcare, Inc. (VMD).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.